First report of inclisiran utilization for hypercholesterolemia treatment in real-world clinical settings in a middle east population (2024)
- Authors:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1016/j.clinthera.2023.12.003
- Subjects: HIPERCOLESTEROLEMIA; INFLAMAÇÃO; FÁRMACOS (SISTEMA CARDIOVASCULAR); PREVENÇÃO DE DOENÇAS
- Language: Inglês
- Imprenta:
- Publisher place: Bridgewater
- Date published: 2024
- Source:
- Título: Clinical therapeutics
- ISSN: 0149-2918
- Volume/Número/Paginação/Ano: v. 46, n. 3, p. 186-193, 2024
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
IQBAL, Sajid et al. First report of inclisiran utilization for hypercholesterolemia treatment in real-world clinical settings in a middle east population. Clinical therapeutics, v. 46, n. 3, p. 186-193, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/76867. Acesso em: 19 fev. 2026. -
APA
Iqbal, S., Sabbour, H. M., Ashraf, T., Santos Filho, R. D. dos, & Buckley, A. (2024). First report of inclisiran utilization for hypercholesterolemia treatment in real-world clinical settings in a middle east population. Clinical therapeutics, 46( 3), 186-193. doi:10.1016/j.clinthera.2023.12.003 -
NLM
Iqbal S, Sabbour HM, Ashraf T, Santos Filho RD dos, Buckley A. First report of inclisiran utilization for hypercholesterolemia treatment in real-world clinical settings in a middle east population [Internet]. Clinical therapeutics. 2024 ; 46( 3): 186-193.[citado 2026 fev. 19 ] Available from: https://observatorio.fm.usp.br/handle/OPI/76867 -
Vancouver
Iqbal S, Sabbour HM, Ashraf T, Santos Filho RD dos, Buckley A. First report of inclisiran utilization for hypercholesterolemia treatment in real-world clinical settings in a middle east population [Internet]. Clinical therapeutics. 2024 ; 46( 3): 186-193.[citado 2026 fev. 19 ] Available from: https://observatorio.fm.usp.br/handle/OPI/76867 - Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- Familial hypercholesterolaemia: PCSK9 inhibitors are coming [comentário]
- Relation of Hepatic Steatosis to Atherogenic Dyslipidemia
- Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome
- Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
- USPSTF recommendation on screening for lipid disorders in children and adolescents. [Carta]
- Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity
- Relation Between Self-Reported Physical Activity Level, Fitness, and Cardiometabolic Risk
- Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know
- The Role of Statins in Current Guidelines
Informações sobre o DOI: 10.1016/j.clinthera.2023.12.003 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
